Microbot Medical stock price target maintained at $12 by H.C. Wainwright

H.C. Wainwright has maintained a Buy rating and a $12.00 price target for Microbot Medical (NASDAQ:MBOT) following the company's recent patent approvals in the U.S., Japan, China, and Canada. The approvals bring Microbot Medical's global portfolio to 44 issued patents and 49 pending patent applications, supporting the protection of its FDA-cleared robotic system, LIBERTY.

Despite the company's weak financial health score, the stock's technical position is currently oversold, presenting an opportunity for investors. Microbot Medical reported a significant revenue increase of 100% for the second quarter of 2026, reaching $241,000, although it still recorded a net loss of $5.6 million. The company has also signed a three-year exclusive distribution agreement with Medtechnica in Israel, with initial orders expected in the fourth quarter of 2026.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.